

PRODUCT  
CANDIDATE:  
**CF-101** (piclidenoson)

**\$600M**

Annual Canadian market for  
plaque psoriasis treatments

**\$42M**

Annual Canadian market for  
moderate to severe plaque  
psoriasis treatments

Sources:  
Canadian Dermatology Association,  
IQVIA CompuScript Sep 2023 MAT



Acquired marketing rights from:	Can-Fite BioPharma (NYSE:CANF)	
Indication:	Plaque psoriasis	
Advantage:	Demonstrated increased efficacy with lower adverse events	
Regulatory next step:	Phase III COMFORT study completed, Pivotal Phase III study expected early 2024	
Timeline	Pivotal trial results expected by 2026	